Is palbociclib/palbociclib a targeted therapy?

Palbociclib/Palbociclib undoubtedly belongs to this category of targeted therapy drugs. As an innovative oral anti-cancer drug, palbociclib specifically targets cyclin-dependent kinases (CDKs) 4 and 6, thereby playing a key role in cancer treatment.

Pabociclib is particularly indicated for use in combination with letrozole 1) an aromatase inhibitor as the initial endocrine agent in the treatment of postmenopausal women or men with advanced breast cancer who are hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative; or 2) fulvestrant in patients with disease progression after endocrine therapy.

Targeted therapy drugs refer to drugs that can selectively act on specific targets of tumor cells, thereby interfering with their growth, spread and metastasis. Compared with traditional chemotherapy drugs, targeted therapy drugs are more specific and have lower side effects. They can kill tumor cells more accurately and reduce damage to normal cells.

Palbociclib is particularly widely used in the treatment of breast cancer. It is mainly used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. By combining with aromatase inhibitors, palbociclib can significantly prolong patient survival and improve treatment effects.

In addition, palbociclib, as a targeted therapy, has other advantages. For example, it can reduce the drug resistance of tumor cells and improve the sensitivity of chemotherapy drugs; at the same time, it can also improve the quality of life of patients and reduce discomfort and side effects during chemotherapy.

In summary, palbociclib, as a targeted therapy drug, plays an important role in the treatment of breast cancer. Its advent not only provides new treatment options for breast cancer patients, but also opens up a new direction for future cancer treatment.